PT-141: A Comprehensive Research Monograph

Overview

PT-141, also known by its generic name bremelanotide, is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist with preferential activity at the MC3R and MC4R receptor subtypes. It is structurally derived from Melanotan II (MT-II) through the removal of the C-terminal amide group, yielding the free acid form with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a molecular weight of 1025.18 g/mol. PT-141 holds the distinction of being the first melanocortin-based therapeutic to receive FDA approval, marketed under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in June 2019.

The development of PT-141 represents a landmark in both melanocortin pharmacology and sexual medicine. Its mechanism of action is fundamentally different from all previously available pharmacological interventions for sexual dysfunction. While phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil act through peripheral vascular mechanisms to enhance blood flow to erectile tissue, PT-141 operates through central nervous system (CNS) melanocortin pathways that modulate the neurological substrates of sexual desire and arousal. This distinction was first recognized during clinical studies of Melanotan II, when researchers observed that subjects experienced spontaneous pro-erectile effects and increased sexual desire as an unexpected secondary finding during pigmentation trials.

The cyclic lactam structure of PT-141 is formed by a bridge between the side chains of aspartic acid and lysine, conferring enhanced metabolic stability compared to linear melanocortin analogs. The norleucine substitution at the first position and D-phenylalanine at the sixth position are critical structural modifications inherited from the MT-II scaffold that dramatically increase receptor binding affinity and resistance to enzymatic degradation relative to the native alpha-melanocyte-stimulating hormone (alpha-MSH) sequence.

The journey from MT-II to PT-141 represents an important example of pharmacological optimization: by converting the C-terminal amide to a free acid, researchers achieved a compound with reduced activity at MC1R (the melanogenesis receptor) and MC5R while maintaining potent agonism at MC3R and MC4R, the receptor subtypes most relevant to CNS-mediated sexual function. This selectivity profile made PT-141 a more targeted pharmacological agent for sexual function research compared to the broadly active MT-II parent compound.

Mechanism of Action

PT-141 operates through a fundamentally different mechanism than any other pharmacological agent studied for sexual dysfunction. Its effects are mediated centrally through melanocortin receptor signaling in the brain, acting on the neural circuitry that underlies desire, arousal, and motivated sexual behavior.

MC3R and MC4R Agonism

PT-141 functions as a non-selective agonist at melanocortin-3 receptors (MC3R) and melanocortin-4 receptors (MC4R), both of which are expressed in hypothalamic nuclei and limbic structures critical for sexual behavior. MC4R is particularly enriched in the medial preoptic area (MPOA), the paraventricular nucleus (PVN) of the hypothalamus, and the ventral tegmental area (VTA) — brain regions that constitute core nodes of the neural circuitry governing sexual motivation and arousal.

The binding of PT-141 to MC4R triggers G-protein-coupled receptor signaling through both Gs and Gq pathways. Gs coupling activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). Gq coupling activates phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilize intracellular calcium and activate protein kinase C (PKC). This dual signaling cascade influences the release of multiple neurotransmitters critical for sexual function, including dopamine from the VTA and oxytocin from the PVN.

MC4R activation in the PVN stimulates oxytocinergic neurons that project to the spinal cord, where oxytocin acts on sacral parasympathetic neurons to facilitate erectile response. Simultaneously, MC4R signaling in the MPOA and VTA enhances dopaminergic transmission in mesolimbic reward circuits, which is the neurochemical substrate underlying increased sexual motivation and desire. This coordinated activation of oxytocinergic and dopaminergic pathways explains PT-141’s unique ability to affect both the motivational (desire) and physiological (arousal/erection) components of sexual response.

Central Nervous System-Mediated Mechanism

A defining feature of PT-141’s pharmacology is that it acts through central nervous system pathways rather than peripheral vascular mechanisms. This was definitively established through a series of elegant preclinical experiments. In animal models, PT-141 induced penile erection through a mechanism that was blocked by intracerebroventricular (ICV) administration of the melanocortin receptor antagonist SHU-9119, but was unaffected by peripheral alpha-adrenergic or nitric oxide synthase blockade. These findings confirmed that PT-141’s pro-erectile effects originate in the brain rather than in the peripheral vasculature.

Functional neuroimaging studies in human subjects have provided additional evidence for the central mechanism. Bremelanotide administration was associated with increased activation in brain regions known to mediate sexual arousal processing, including the anterior cingulate cortex, insula, and amygdala. These regions are involved in the integration of interoceptive signals, emotional salience, and reward processing — functions that collectively constitute the subjective experience of sexual desire.

The CNS-mediated mechanism has profound clinical implications. Because PT-141 acts upstream of the peripheral hemodynamic response, it can enhance both subjective desire and physiological arousal. This explains why PT-141 demonstrated efficacy in populations where PDE5 inhibitors had failed, including men with erectile dysfunction refractory to sildenafil and women with HSDD, a condition for which peripheral vasodilator approaches have shown minimal benefit.

Structural Relationship to Melanotan II

PT-141 is both a metabolite and a deliberate structural derivative of Melanotan II. The conversion from amide (MT-II) to free acid (PT-141) represents a subtle but pharmacologically significant modification. In receptor binding assays, PT-141 retains high affinity at MC3R (Ki approximately 20 nM) and MC4R (Ki approximately 3 nM) while showing substantially reduced binding at MC1R (the pigmentation receptor) compared to MT-II. This shift in selectivity profile was a key factor in the decision to develop PT-141 rather than MT-II as a therapeutic candidate for sexual dysfunction.

The reduced MC1R activity means that PT-141 produces significantly less melanogenic stimulation than MT-II, minimizing the pigmentation side effects that had been a dose-limiting factor in MT-II clinical studies. However, PT-141 does retain some residual MC1R activity, which accounts for the facial flushing observed in a substantial proportion of subjects in clinical trials — a response mediated at least in part by melanocortin receptor activation in cutaneous vasculature.

Downstream Neurotransmitter Cascades

The activation of melanocortin receptors by PT-141 triggers a cascade of downstream neurotransmitter events that collectively mediate the sexual response:

• Dopamine release: MC4R activation in the VTA and nucleus accumbens enhances dopaminergic transmission in mesolimbic reward pathways, increasing sexual motivation and incentive salience
• Oxytocin release: PVN oxytocinergic neurons activated by MC4R signaling project to the spinal cord and limbic structures, facilitating both erectile physiology and pair-bonding/affiliative behavior
• Norepinephrine modulation: Melanocortin signaling modulates noradrenergic tone in the locus coeruleus, potentially influencing arousal state and attention to sexual stimuli
• Endocannabinoid interaction: Emerging evidence suggests melanocortin signaling may interact with the endocannabinoid system in hypothalamic circuits, adding another modulatory layer to appetite and reward-related behaviors

Pharmacokinetics

The pharmacokinetic profile of PT-141 has been characterized through multiple Phase I and Phase II studies, providing a detailed understanding of its absorption, distribution, metabolism, and elimination characteristics.

Absorption and Bioavailability

Following subcutaneous injection of the approved 1.75 mg dose, PT-141 is rapidly absorbed with a time to peak plasma concentration (Tmax) of approximately 1 hour (range 0.5-1.5 hours). The absolute bioavailability via the subcutaneous route is approximately 100% relative to intravenous administration, indicating complete systemic absorption from the injection site. Peak plasma concentrations (Cmax) of approximately 7-9 ng/mL are achieved at the therapeutic dose.

Intranasal administration was investigated in earlier clinical development programs, achieving Tmax values of approximately 30-45 minutes but with lower and more variable bioavailability (estimated 5-10%) compared to subcutaneous injection. The intranasal route was ultimately discontinued in clinical development due to concerns about blood pressure elevation at the higher doses required to compensate for lower bioavailability.

Distribution

PT-141 demonstrates extensive tissue distribution following systemic absorption, with a volume of distribution of approximately 79.8 L, substantially exceeding total body water volume and indicating significant partitioning into tissues. Importantly, radiolabeled studies in animal models have confirmed that PT-141 crosses the blood-brain barrier, which is essential for its central mechanism of action. Plasma protein binding is approximately 21%, with the majority of circulating PT-141 present in the unbound form.

Metabolism and Elimination

PT-141 is metabolized primarily by hydrolysis and amide bond cleavage, with multiple metabolites identified in plasma and urine. The primary metabolic pathways involve cleavage of the linear portion of the peptide while the cyclic core structure is relatively resistant to enzymatic degradation. The terminal elimination half-life is approximately 2.7 hours following subcutaneous administration, which is consistent with the observed duration of pharmacological effect (6-12 hours for sexual function endpoints, with some effects persisting up to 24 hours).

Renal excretion of unchanged PT-141 accounts for approximately 64.8% of the administered dose, with hepatic metabolism and biliary excretion contributing to the remainder. The relatively short half-life supports the on-demand dosing paradigm employed in clinical use, allowing drug levels to return to baseline well before the next potential dose.

Pharmacokinetic-Pharmacodynamic Relationship

The relationship between PT-141 plasma concentrations and pharmacological effects does not follow a simple linear model. While Cmax is reached at approximately 1 hour, clinical effects on sexual desire and arousal typically emerge within 30-60 minutes and persist for 6-12 hours, well beyond the period of peak plasma concentrations. This temporal dissociation between plasma levels and clinical effect suggests that PT-141 initiates a cascade of downstream neurochemical events (dopamine release, oxytocin secretion, neuroendocrine modulation) that persist after the parent compound has been largely cleared from plasma.

Research Applications

Sexual Function Research — Female HSDD

The pivotal RECONNECT Phase III clinical trials established the efficacy of bremelanotide for the treatment of HSDD in premenopausal women. These two randomized, double-blind, placebo-controlled studies (RECONNECT 1 and RECONNECT 2) enrolled over 1,200 women across multiple centers and demonstrated:

• Increased sexual desire: Statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain score compared to placebo, with a mean treatment difference of approximately 0.5 points on the 1.2-6.0 scale
• Reduced distress: Significant reductions in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score measuring distress related to low sexual desire, with a mean treatment difference of approximately -0.7 points
• Self-administered dosing: PT-141 was administered subcutaneously on an as-needed basis approximately 45 minutes before anticipated sexual activity, with a maximum frequency of once per 24 hours
• Sustained efficacy: Treatment effects were maintained over the 24-week study duration without evidence of tachyphylaxis or tolerance development
• Clinically meaningful response: Approximately 50% of bremelanotide-treated patients achieved a clinically meaningful improvement in desire, compared to approximately 36% of placebo-treated patients

The RECONNECT trials were landmark studies because they demonstrated that a centrally acting melanocortin agonist could effectively treat a disorder of sexual desire — a condition for which few pharmacological options existed and for which peripheral vasodilator approaches had consistently failed.

Sexual Function Research — Male Applications

Earlier Phase II research evaluated PT-141 in male subjects with erectile dysfunction through multiple clinical studies:

• Pro-erectile effects: Subcutaneous administration produced clinically significant erectile responses in men with ED, including those who had not responded to PDE5 inhibitors, demonstrating that the central melanocortin mechanism can bypass peripheral vascular impairment
• CNS mechanism confirmation: The pro-erectile response was not dependent on peripheral vasodilatory mechanisms, as confirmed by the absence of significant changes in penile blood flow parameters independent of erection, distinguishing PT-141 from PDE5 inhibitors and prostaglandin E1
• Dose-response relationship: Studies established a clear dose-dependent response pattern, with subcutaneous doses of 4-10 mg producing the most robust effects in early studies, though subsequent optimization reduced the target dose
• Intranasal studies: Early investigations of intranasal PT-141 in male ED demonstrated rapid onset of pro-erectile effects, though this route was later abandoned due to blood pressure concerns at higher doses

Melanocortin Receptor Pharmacology

Beyond sexual function, PT-141 has served as an important pharmacological tool for understanding melanocortin receptor biology:

• MC4R signaling characterization: PT-141 has been used to map MC4R-mediated signaling pathways in the CNS, helping establish the receptor’s role as a critical integrator of sexual, appetitive, and reward-related behaviors
• Receptor desensitization studies: Research into melanocortin receptor downregulation and tolerance mechanisms using repeated PT-141 dosing has informed understanding of GPCR desensitization in the melanocortin system
• Behavioral neuroscience: Investigation of melanocortin involvement in reward, motivation, and appetitive behaviors has benefited from PT-141’s well-characterized pharmacology and favorable CNS penetration
• Cross-talk with other neuropeptide systems: Studies have revealed interactions between melanocortin signaling and opioid, dopaminergic, and oxytocinergic pathways, with PT-141 serving as a key pharmacological probe

Appetite and Energy Homeostasis Research

Although PT-141’s development focused on sexual function, its activity at MC3R and MC4R also positions it as a relevant tool for energy homeostasis research. MC4R is a well-established regulator of food intake and energy expenditure, and PT-141 administration has been shown to produce anorexigenic effects in animal models. While these appetite effects were considered off-target for the sexual dysfunction indication, they provide additional insight into the overlapping melanocortin circuitry that governs motivated behaviors.

Safety Profile

The safety of bremelanotide has been evaluated in the RECONNECT pivotal trials and in a 52-week open-label extension study encompassing over 3,600 patient-years of exposure. The safety profile is generally consistent with the known pharmacology of melanocortin receptor agonism.

Common Adverse Effects

The most frequently reported adverse events in clinical trials include:

• Nausea: The most common adverse effect, reported in approximately 40% of patients in clinical trials. Nausea typically occurs within 1 hour of dosing, is transient (resolving within 2-3 hours), and tends to diminish with repeated use. Nausea is likely mediated by MC4R activation in brainstem emetic centers.
• Flushing: Reported in approximately 20% of patients, manifesting as warmth and redness primarily in the face and upper body. This is likely mediated by residual MC1R activity on cutaneous vascular smooth muscle.
• Injection site reactions: Mild erythema, pruritus, or bruising at the subcutaneous injection site, reported in approximately 13% of patients.
• Headache: Reported in approximately 11% of patients, typically mild and self-limiting.

Cardiovascular Monitoring

A transient increase in systolic blood pressure of approximately 2-3 mmHg and a reduction in heart rate of approximately 2-3 bpm have been observed following PT-141 administration. While these hemodynamic changes are clinically modest in normotensive individuals, bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease as a precautionary measure. The earlier intranasal formulation produced more pronounced blood pressure increases at higher doses, which contributed to the decision to develop the subcutaneous route instead.

Pigmentation Effects

Some subjects in clinical trials reported darkening of facial skin, gingival hyperpigmentation, or darkening of existing nevi. These pigmentation changes are attributed to residual MC1R activity and were more commonly observed with repeated dosing over extended periods. The pigmentation effects were generally mild and reversible upon discontinuation.

Reproductive Safety

Bremelanotide is not recommended during pregnancy. Animal studies at supratherapeutic doses showed embryofetal toxicity, and the drug is classified as pregnancy Category X. The labeling recommends a negative pregnancy test before initiating treatment and the use of effective contraception during therapy.

Dosing in Research

The following table summarizes dosing parameters observed across published preclinical and clinical research studies of PT-141. All values are drawn from peer-reviewed literature and are presented for informational purposes only.

Molecular Properties

Storage and Handling for Research

PT-141 should be stored as a lyophilized powder at -20°C for long-term stability. The cyclic lactam structure provides good intrinsic stability against proteolytic degradation, but the peptide contains residues susceptible to oxidation (notably tryptophan) and deamidation, so exposure to light, heat, moisture, and extreme pH should be minimized. Lyophilized PT-141 maintains stability for at least 24 months when stored properly at -20°C in sealed, desiccated vials.

Once reconstituted with bacteriostatic water, solutions should be stored at 2-8°C, protected from light, and used within 30 days. For research applications requiring extended storage of reconstituted material, aliquoting into single-use volumes and storing at -20°C is recommended to avoid repeated freeze-thaw cycles.

Current Research Landscape

PT-141 and the broader melanocortin system continue to be active areas of scientific investigation. The 2019 FDA approval of bremelanotide validated the melanocortin pathway as a druggable target for disorders of sexual desire, opening new avenues for both clinical application and basic research. Key areas of ongoing and future research include:

1. Expanded clinical indications: Investigation of bremelanotide for HSDD in postmenopausal women is ongoing, along with renewed interest in male sexual dysfunction applications. Studies are also exploring potential efficacy in sexual dysfunction secondary to antidepressant use (SSRI-induced sexual dysfunction), a highly prevalent and undertreated condition.

2. Alternative delivery systems: Research into intranasal, sublingual, and transdermal delivery systems aims to improve patient convenience and pharmacokinetic profiles. A nasal spray formulation is currently in development that may achieve adequate CNS delivery without the blood pressure elevation concerns that limited earlier intranasal programs.

3. Melanocortin pathway mapping: PT-141 continues to serve as a critical pharmacological tool for mapping CNS melanocortin circuitry. Advanced neuroimaging techniques, including fMRI and PET with melanocortin receptor radioligands, are providing increasingly detailed maps of melanocortin receptor distribution and activation patterns in the human brain.

4. Combination therapeutic approaches: Studies examining PT-141 alongside other neuroactive agents for refractory sexual dysfunction are in early stages. Combinations with testosterone, dopamine agonists, and oxytocin are being investigated in preclinical models.

5. Novel melanocortin analogs: Structure-activity relationship research using PT-141 as a lead compound continues to generate next-generation melanocortin therapeutics with improved selectivity profiles, longer durations of action, or oral bioavailability.

6. Melanocortin system in psychiatry: Emerging research is investigating the intersection of melanocortin signaling with mood, anxiety, and stress-related disorders, given the overlap between the neural circuits involved in sexual motivation and emotional regulation. PT-141 may serve as a pharmacological probe in these studies.

References

The studies referenced throughout this monograph represent a selection of the published literature on PT-141 (bremelanotide) and melanocortin-mediated sexual function. For a comprehensive bibliography, researchers are encouraged to search PubMed and Google Scholar using the terms “bremelanotide,” “PT-141,” “melanocortin sexual function,” or “MC4R agonist sexual behavior” for the most current publications.